Telehealth in Lewy Body Dementia

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-100
SponsorUniversity of Florida

About this trial

Lewy body dementia (LBD) is the 2nd most common neurodegenerative dementia in the US. Optimal care requires an interdisciplinary approach, however often faced barriers include rural residence, limited access to specialists, travel distance, limited awareness of resources, and physical, cognitive, and behavioral impairments making travel to appointments challenging. Delivering interdisciplinary care remotely using video technology has the potential to improve access to care for patients with LBD.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

LBD diagnosis by a dementia or movement disorders specialist

Clinician-determined mild-moderate dementia severity

Internet access with a Zoom-compatible device

Caregiver who resides in the patient's home and is willing to participate

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • Tele-neurohub

    Behavioral

    Interdisciplinary care delivered using telemedicine (zoom) technology which includes neurologist, physical, occupational and speech therapy, social worker and dietician.

Treatment groups

106 Participants
are divided into 2 treatment groups
Group A: Tele-neurohubExperimental treatment 1 intervention
Group B: Usual care groupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Number of completed tele-health visits

Feasibility will be determined by completion of at least 75% telehealth visits by the intervention cohort

Time frame
6 months

Secondary outcomes

1

Satisfaction assessed by Patient Assessment of Communication of Telehealth questionnaire.

Acceptability will be determined by at least 80% of dyads reporting being "satisfied" or "highly satisfied" on the Patient Assessment of Communication of Telehealth questionnaire.

Time frame
6 months
2

Appropriateness assessed by Intervention Appropriateness Measure

Appropriateness will be determined by the Intervention Appropriateness Measure, higher scores indicate greater appropriateness

Time frame
6 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Florida

Lead sponsor

National Institute on Aging (NIA)

Collaborator